Literature DB >> 26612823

Sequence-non-specific effects generated by various types of RNA interference triggers.

Marta Olejniczak1, Martyna O Urbanek2, Edyta Jaworska3, Lukasz Witucki4, Michal W Szczesniak5, Izabela Makalowska6, Wlodzimierz J Krzyzosiak7.   

Abstract

RNA interference triggers such as short interfering RNA (siRNA) or genetically encoded short hairpin RNA (shRNA) and artificial miRNA (sh-miR) are widely used to silence the expression of specific genes. In addition to silencing selected targets, RNAi reagents may induce various side effects, including immune responses. To determine the molecular markers of immune response activation when using RNAi reagents, we analyzed the results of experiments gathered in the RNAimmuno (v 2.0) and GEO Profiles databases. To better characterize and compare cellular responses to various RNAi reagents in one experimental system, we designed a reagent series in corresponding siRNA, D-siRNA, shRNA and sh-miR forms. To exclude sequence-specific effects the reagents targeted 3 different transcripts (Luc, ATXN3 and HTT). We demonstrate that RNAi reagents induce a broad variety of sequence-non-specific effects, including the deregulation of cellular miRNA levels. Typical siRNAs are weak stimulators of interferon response but may saturate the miRNA biogenesis pathway, leading to the downregulation of highly expressed miRNAs, whereas plasmid-based reagents induce known markers of immune response and may alter miRNA levels and their isomiR composition.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Immune response; Off-target; RNA interference; RNAimmuno; isomiRs; miRNA; siRNA

Mesh:

Substances:

Year:  2015        PMID: 26612823     DOI: 10.1016/j.bbagrm.2015.11.005

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Self-delivering RNAi compounds as therapeutic agents in the central nervous system to enhance axonal regeneration after injury.

Authors:  Sarah A Woller; Joerg Ruschel; Barbara Morquette; James Cardia; Dinxue Yan; Katherine Holton; Taisia Shmushkovich; Emily Niederst; Karen Bulock; Alexey Wolfson; Matthew Abbinanti; Alyson E Fournier; Lisa McKerracher; Kenneth M Rosen
Journal:  iScience       Date:  2022-05-10

Review 2.  Stress-induced changes in miRNA biogenesis and functioning.

Authors:  Marta Olejniczak; Anna Kotowska-Zimmer; Wlodzimierz Krzyzosiak
Journal:  Cell Mol Life Sci       Date:  2017-07-17       Impact factor: 9.261

Review 3.  Genetic compensation: A phenomenon in search of mechanisms.

Authors:  Mohamed A El-Brolosy; Didier Y R Stainier
Journal:  PLoS Genet       Date:  2017-07-13       Impact factor: 5.917

4.  Preclinical Evaluation of a Lentiviral Vector for Huntingtin Silencing.

Authors:  Karine Cambon; Virginie Zimmer; Sylvain Martineau; Marie-Claude Gaillard; Margot Jarrige; Aurore Bugi; Jana Miniarikova; Maria Rey; Raymonde Hassig; Noelle Dufour; Gwenaelle Auregan; Philippe Hantraye; Anselme L Perrier; Nicole Déglon
Journal:  Mol Ther Methods Clin Dev       Date:  2017-05-11       Impact factor: 6.698

Review 5.  The state of gene therapy research in Africa, its significance and implications for the future.

Authors:  P Arbuthnot; M B Maepa; A Ely; M S Pepper
Journal:  Gene Ther       Date:  2017-07-10       Impact factor: 5.250

Review 6.  Fetal gene therapy and pharmacotherapy to treat congenital hearing loss and vestibular dysfunction.

Authors:  Michelle L Hastings; John V Brigande
Journal:  Hear Res       Date:  2020-03-05       Impact factor: 3.208

Review 7.  Reverse-genetics studies of lncRNAs-what we have learnt and paths forward.

Authors:  Fan Gao; Ye Cai; Philipp Kapranov; Dongyang Xu
Journal:  Genome Biol       Date:  2020-04-14       Impact factor: 13.583

8.  Generation of New Isogenic Models of Huntington's Disease Using CRISPR-Cas9 Technology.

Authors:  Magdalena Dabrowska; Agata Ciolak; Emilia Kozlowska; Agnieszka Fiszer; Marta Olejniczak
Journal:  Int J Mol Sci       Date:  2020-03-08       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.